The Latest Breaking News from Oppenheimer

Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down 1.62% over the last 24 hours, at $10.94 per share.

Oppenheimer analyst Brian Schwartz upgraded Zeta Global Holdings Corp (NYSE:ZETA) to Outperform from Perform with a $20 price target (49.5% upside).  Zeta is an omnichannel data-driven cloud platform offering enterprises with consumer intelligence and marketing automation software.  Schwartz saw a "substantial upside from current prices" based on valuation, improving fundamentals, and transparency.  Zeta's revenue growth…

Analysts had mixed opinions on Alteryx Inc (NYSE:AYX) post Q4 beat. Alteryx is a software company that provides self-service data analytics software. Oppenheimer analyst Ittai Kidron lowered the firm's price target on Alteryx to $85 from $105 (62.9% upside) to reflect multiple realignments while keeping an Outperform rating on the shares.  The analyst notes Alteryx's Q4…

Oppenheimer analyst Ian Zaffino upgraded Six Flags Entertainment Corp (NYSE:SIX) to Outperform from Perform with a $54 price target, implying a 32.78% upside. The analyst believes the company's newly-appointed CEO Selim Bassoul's strategy of "premiumization" is the right one. The company has been focused on attendance growth for too long and has neglected obvious pricing…